S1 versus taxanes for HER2-negative metastatic breast cancer
Mené au Japon sur 618 patientes atteintes d'un cancer métastatique du sein HER2-, cet essai multicentrique randomisé de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de taxanes (docétaxel, paclitaxel) et du S-1 en traitement de première ligne
In The Lancet Oncology, Tsutomu Takashima and colleagues present the results of SELECT BC, a phase 3, non-inferiority, randomised trial comparing the oral fluoropyrimidine S-1 (containing tegafur, gimeracil, and oteracil) with a taxane (investigator's choice) as first-line chemotherapy for HER2-negative metastatic breast cancer. The study showed that S-1 was non-inferior to taxanes with respect to overall survival, the primary endpoint, and also showed many relevant advantages in terms of side-effects and quality of life.
The Lancet Oncology , commentaire, 2014